CompetitionCurrent standard of care calcineurin inhibitors adversely impact transplant longevity, patient health, and quality of life, representing a clear opportunity for Tego.
Financial HealthEledon reported having $124.9M in cash, cash equivalents, and short-term investments, which is expected to fund operations through the end of the year.